This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martino, E. Articles by Braverman, L. E. Search for Related Content PubMed PubMed Citation Articles by Martino, E. Articles by Braverman, L. E.

The Effects of Amiodarone on the Thyroid¹

Dipartimento di Endocrinologia e Metabolismo (E.M., F.B.), University of Pisa, Pisa, Italy 56124; Cattedra di Endocrinologia (L.B.), University of Insubria, Varese, Italy; Section of Endocrinology, Diabetes and Nutrition (L.E.B.), Boston Medical Center, Boston, Massachusetts 02118-2393

Amiodarone is a benzofuranic-derivative iodine-rich drug widely used for the treatment of tachyarrhythmias and, to a lesser extent, of ischemic heart disease. It often causes changes in thyroid function tests (typically an increase in serum T₄ and rT₃, and a decrease in serum T₃, concentrations), mainly related to the inhibition of 5'-deiodinase activity, resulting in a decrease in the generation of T₃ from T₄ and a decrease in the clearance of rT₃. In 14–18% of amiodarone-treated patients, there is overt thyroid dysfunction, either amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH). Both AIT and AIH may develop either in apparently normal thyroid glands or in glands with preexisting, clinically silent abnormalities. Preexisting Hashimoto’s thyroiditis is a definite risk factor for the occurrence of AIH. The pathogenesis of iodine-induced AIH is related to a failure to escape from the acute Wolff-Chaikoff effect due to defects in thyroid hormonogenesis, and, in patients with positive thyroid autoantibody tests, to concomitant Hashimoto’s thyroiditis. AIT is primarily related to excess iodine-induced thyroid hormone synthesis in an abnormal thyroid gland (type I AIT) or to amiodarone-related destructive thyroiditis (type II AIT), but mixed forms frequently exist. Treatment of AIH consists of L-T₄ replacement while continuing amiodarone therapy; alternatively, if feasible, amiodarone can be discontinued, especially in the absence of thyroid abnormalities, and the natural course toward euthyroidism can be accelerated by a short course of potassium perchlorate treatment. In type I AIT the main medical treatment consists of the simultaneous administration of thionamides and potassium perchlorate, while in type II AIT, glucocorticoids are the most useful therapeutic option. Mixed forms are best treated with a combination of thionamides, potassium perchlorate, and glucocorticoids. Radioiodine therapy is usually not feasible due to the low thyroidal radioiodine uptake, while thyroidectomy can be performed in cases resistant to medical therapy, with a slightly increased surgical risk.

This article has been cited by other articles:

				E. S. Mittra, R. D. Niederkohr, C. Rodriguez, T. El-Maghraby, and I. R. McDougall Uncommon Causes of Thyrotoxicosis J. Nucl. Med., February 1, 2008; 49(2): 265 - 278. [Abstract] [Full Text] [PDF]

				I. Klein and S. Danzi Thyroid Disease and the Heart Circulation, October 9, 2007; 116(15): 1725 - 1735. [Abstract] [Full Text] [PDF]

				D. Conen, L. Melly, C. Kaufmann, S. Bilz, P. Ammann, B. Schaer, C. Sticherling, B. Muller, and S. Osswald Amiodarone-Induced Thyrotoxicosis: Clinical Course and Predictors of Outcome J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2350 - 2355. [Abstract] [Full Text] [PDF]

				F. Bogazzi, L. Bartalena, L. Tomisti, G. Rossi, M. L. Tanda, E. Dell'Unto, F. Aghini-Lombardi, and E. Martino Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 556 - 562. [Abstract] [Full Text] [PDF]

				L D K E Premawardhana and J H Lazarus Management of thyroid disorders. Postgrad. Med. J., September 1, 2006; 82(971): 552 - 558. [Abstract] [Full Text] [PDF]

				R. Porsche and Z. R. Brenner Amiodarone-induced thyroid dysfunction. Crit. Care Nurse, June 1, 2006; 26(3): 34 - 41. [Full Text] [PDF]

				S. Tedelind, F. Larsson, C. Johanson, H. C. van Beeren, W. M. Wiersinga, E. Nystrom, and M. Nilsson Amiodarone Inhibits Thyroidal Iodide Transport in Vitro by a Cyclic Adenosine 5'-Monophosphate- and Iodine-Independent Mechanism Endocrinology, June 1, 2006; 147(6): 2936 - 2943. [Abstract] [Full Text] [PDF]

				A. J O'Sullivan, M. Lewis, and T. Diamond Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur. J. Endocrinol., April 1, 2006; 154(4): 533 - 536. [Abstract] [Full Text] [PDF]

				L. Roten, R. A Schoenenberger, S. Krahenbuhl, and R. G Schlienger Rhabdomyolysis in Association with Simvastatin and Amiodarone Ann. Pharmacother., June 1, 2004; 38(6): 978 - 981. [Abstract] [Full Text] [PDF]

				J.-S. Hermida, E. Tcheng, G. Jarry, V. Moullart, S. Arlot, J.-L. Rey, J. Delonca, and C. Schvartz Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias Europace, January 1, 2004; 6(2): 169 - 174. [Abstract] [Full Text] [PDF]

				Y. Tomer and T. F. Davies Searching for the Autoimmune Thyroid Disease Susceptibility Genes: From Gene Mapping to Gene Function Endocr. Rev., October 1, 2003; 24(5): 694 - 717. [Abstract] [Full Text] [PDF]

				E. N. Pearce, A. P. Farwell, and L. E. Braverman Thyroiditis N. Engl. J. Med., June 26, 2003; 348(26): 2646 - 2655. [Full Text] [PDF]

				F. Bogazzi, L. Bartalena, C. Cosci, S. Brogioni, E. Dell'Unto, L. Grasso, F. Aghini-Lombardi, G. Rossi, A. Pinchera, L. E. Braverman, et al. Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1999 - 2002. [Abstract] [Full Text] [PDF]

				Using oral amiodarone DTB, February 1, 2003; 41(2): 9 - 12. [Abstract] [Full Text] [PDF]

				O. Dohan, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C. S. Ginter, and N. Carrasco The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance Endocr. Rev., February 1, 2003; 24(1): 48 - 77. [Abstract] [Full Text] [PDF]

				E. N. Pearce, A. R. Gerber, D. B. Gootnick, L. K. Khan, R. Li, S. Pino, and L. E. Braverman Effects of Chronic Iodine Excess in a Cohort of Long-Term American Workers in West Africa J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5499 - 5502. [Abstract] [Full Text] [PDF]

				F. Osman, J. A. Franklyn, M. C. Sheppard, and M. D. Gammage Successful Treatment of Amiodarone-Induced Thyrotoxicosis Circulation, March 19, 2002; 105(11): 1275 - 1277. [Abstract] [Full Text] [PDF]

				A. C. Bianco, D. Salvatore, B. Gereben, M. J. Berry, and P. R. Larsen Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocr. Rev., February 1, 2002; 23(1): 38 - 89. [Abstract] [Full Text] [PDF]